New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:42 EDTHEBHemispherx summarizes clinical results of Phase I/II study of Ampligen
Hemispherx Biopharma presented a summary of the results of its Phase I/II study from the poster presentation entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod --Ampligen, Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" given at the American Society for Microbiology Biodefense Conference in Washington, DC on January 30. When FluMist, a seasonal influenza vaccine, was administered intranasally in conjunction with Ampligen, 92% of the subjects elaborated specific IgA antibodies against at least one of the homologous seasonal vaccine strains. Healthy volunteers also showed, surprisingly, enhanced IgA levels against emerging avian influenza viruses with the potential for causing a pandemic in humans. These antibodies were against one or more of 3 different strains of H5N1, H7N9, and H7N3. Two-thirds of these recipients showed a greater than or equal to 4-fold increase in specific IgA levels over baseline and some had measurable IgA levels one year after receiving FluMist in conjunction with Ampligen. A published challenge study in adults (aged 18-45) indicates that FluMistŪ alone generates ≥4 fold increase in serum HAI antibody response (a level thought to be protective) in 24% of recipients despite the fact that 85% of recipients were estimated to have been protected (Treanor, et al. (2000) Vaccine, 18:899). In Europe FluMistŪ is approved for individuals aged 2-17 compared to ages 2-49 in the US.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
08:37 EDTHEBHemispherx exploring possible research program in Zika Virus
Subscribe for More Information
February 3, 2016
08:46 EDTHEBHemispherx announces voluntary stock purchase plan
Hemispherx Biopharma announced a Voluntary Pay for Stock Plan. Hemispherx Biopharma is seeking to create ownership incentives as well as to provide additional cash for various operational activities. All members of Senior Management, all members of the board, and all employees volunteered to participate. Senior Management believes that this Plan creates significant shareholder value as the participants will voluntarily use up to 20% of their salaries to purchase stock from the company, creating long term incentives for them to reach corporate goals. In addition, the CEO/Chairman and President/CFO, will both voluntarily reduce their salaries further to a cumulative reduction of 50%. The plan goes into effect immediately.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use